Vera Therapeutics (VERA) investor relations material

Introduction and purpose

• FDA granted accelerated approval to TRUTAKNA (atacicept-vymj) for adults with IgA nephropathy at risk for disease progression.

• TRUTAKNA is the first and only BAFF and APRIL inhibitor approved for this indication, addressing key immunological drivers of IgAN.

• The approval marks a significant milestone for patients, the nephrology community, and the company.

Details of approval or decision

• Accelerated approval was based on reduction of proteinuria in adult patients with primary IgA nephropathy, with continued approval contingent on confirmatory clinical benefit in the ongoing ORIGIN 3 trial.

• TRUTAKNA is self-administered as a 150 mg subcutaneous injection once weekly via autoinjector.

• Full prescribing information is available online.

• Confirmatory trial data on eGFR is expected in Q3, potentially supporting full approval.

Impact on industry and stakeholders

• Approximately 160,000 diagnosed IgAN patients in the U.S., with a largely commercially insured population.

• Patient advocacy groups and clinicians highlight the therapy as a significant advancement for those with limited options.

• Patient support program offers insurance and financial assistance to improve access.

• The launch is supported by a fully trained sales force targeting about 6,000 nephrologists.

• Favorable payer mix and extensive pre-approval engagement with payers to support access.